The ZORYVE foam launch coincided with higher reported sales for Arcutis Biotherapeutics. The product launched for scalp and body psoriasis in the US in June 2025, and the company says demand for the foam and its creams lifted sales. In the three months ended June 30, revenue rose from $81.5 million to $129.9 million, turning operating income from a $14.6 million loss into $16.4 million of profit.

That is the clean reading: a fast-growing drug franchise has crossed into three-month profitability. The less tidy detail is on the balance sheet. Cash fell from $72.7 million to $34.1 million, while inventory climbed from $16.3 million to $38.9 million and accounts receivable rose to $155.2 million. Inventory grew more than twice as fast as revenue over the comparable periods. Arcutis does not disclose the cause of the cash decline in the supplied filing details.

The cash-flow picture is not uniformly weak. Capital spending fell 77%, and free-cash-flow margin improved to 6.3%, up 27.1 percentage points from the comparable period. That makes the cash balance harder to read from the income statement alone: the business generated a profitable three months, but fewer dollars were sitting in cash at the reporting date.

Management attributes the top-line growth to patients, not just a new product label. The company disclosed:

"The increase in product revenue, net, for ZORYVE foam was primarily driven by greater patient demand for ZORYVE foam for the treatment of seborrheic dermatitis and the commercial launch of ZORYVE foam for plaque psoriasis of the scalp and body in the United States in June 2025."

Arcutis 10-Q, August 5, 2026

That explanation covers both a demand claim and a launch effect. It also leaves the balance-sheet question intact. Sales are arriving, but a larger share of the reported economics is sitting in receivables and inventory rather than cash.

There is another cost moving underneath the profit line. Six-month research and development expense rose 38%, primarily because a $10.0 million milestone became payable after the first patient was dosed in the ARQ-234 Phase 1a/1b trial. Arcutis also said future R&D spending should continue to increase as that program and ZORYVE label expansions advance:

"We expect research and development expenses to continue to increase in future periods, primarily due to our clinical development program for ARQ-234, as well as the development costs associated with ZORYVE label expansions and lifecycle management efforts."

Arcutis 10-Q, August 5, 2026

For now, the three-month income statement shows operating margin improvement, with operating margin moving from negative 17.9% to positive 12.7%. The wider business is still adding shares too: diluted shares rose 7.0% year over year, which puts some distance between company-level profit and profit per share.

Arcutis finished 2025 with $376.1 million of annual revenue, up 91.3%, while its annual operating margin was still negative 3.3%. The latest filing marks another step in that progression, but the next quarterly report will put the $38.9 million inventory balance back on the scale alongside revenue and cash.